Table 2.
A hazard ratio of kidney outcome (AKI, AKD, and ESRD on dialysis) in patients without prior CKD with using AGs compared with using non-AGs in the Cox model.
| Event, n (%) | Without AGs | With AGs | HR (95% CI) | p value | aHR (95% CI) | p value |
|---|---|---|---|---|---|---|
| Baseline patients | n = 40,547 | n = 40,547 | ||||
| AKI stage (0, 1)* | 206 (0.5) | 318 (0.8) | 1.54 (1.30, 1.84) | < 0.001 | 1.34 (1.00, 1.79) | 0.050 |
| AKI stage (0, 2)* | 114 (0.3) | 126 (0.3) | 1.11 (0.86, 1.43) | 0.426 | 0.99 (0.66, 1.47) | 0.954 |
| AKI stage (0, 3)* | 67 (0.2) | 63 (0.2) | 0.94 (0.67, 1.33) | 0.739 | 0.85 (0.49, 1.47) | 0.560 |
| Patients with AKI | n = 387 | n = 507 | ||||
|---|---|---|---|---|---|---|
| AKD stage (0, 1)† | 39 (10.1) | 63 (12.4) | 1.25 (0.84, 1.87) | 0.272 | 1.46 (0.78, 2.72) | 0.236 |
| AKD stage (0, 2)† | 33 (8.5) | 45 (8.9) | 1.07 (0.68, 1.67) | 0.781 | 0.88 (0.42, 1.84) | 0.738 |
| AKD stage (0, 3)† | 32 (8.3) | 53 (10.5) | 1.29 (0.83, 1.99) | 0.263 | 1.47 (0.82, 2.61) | 0.196 |
| Patients with AKI and AKD | n = 104 | n = 161 | ||||
|---|---|---|---|---|---|---|
| ESRD on dialysis§ | 4 (3.9) | 9 (5.6) | 1.43 (0.44, 4.65) | 0.551 | NA | NA |
AGs, aminoglycosides (parenteral gentamicin, amikacin, and tobramycin); AKI, acute kidney injury; AKD, acute kidney disease; ESRD, end-stage renal disease; HR, hazard ratio; aHR, adjust hazard ratio; NA, not available due to small sample size.
*Model was adjusted by baseline hemoglobin group and baseline albumin group.
†Model was adjusted by baseline hemoglobin group, baseline albumin group and AKI stage.
§Model was adjusted by baseline hemoglobin group, baseline albumin group, AKI stage and AKD stage.